However, we observed that the analysis of the balance between Tregs and CD137+ T cells was more informative of the immunological status of cancer patients, and we proposed the ratio Tregs/CD137+ T cells as a biomarker of survival (16). The gene discussed is TNFRSF9; the disease is cancer.